First UK patient joins Pfizer’s phase 3 DMD gene therapy trialThe first UK patient has enrolled on Pfizer’s phase 3 trial for its Duchenne muscular dystrophy (DMD) gene Share XFirst UK patient joins Pfizer’s phase 3 DMD gene therapy trialhttps://pharmaphorum.com/news/first-uk-patient-joins-pfizers-phase-3-dmd-gene-therapy-trial/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Catabasis craters after giving up on muscular dystrophy leadCatabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after Share XCatabasis craters after giving up on muscular dystrophy leadhttps://pharmaphorum.com/news/catabasis-craters-after-giving-up-on-muscular-dystrophy-lead/
NS Pharma takes on Sarepta as FDA approves DMD drugThe FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Share XNS Pharma takes on Sarepta as FDA approves DMD drughttps://pharmaphorum.com/news/ns-pharma-sarepta-fda-approves-dmd-drug/
Roche snaps up ex-US rights to Sarepta’s DMD gene therapyRoche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar Share XRoche snaps up ex-US rights to Sarepta’s DMD gene therapyhttps://pharmaphorum.com/news/roche-snaps-up-ex-us-rights-to-sareptas-dmd-gene-therapy/
Solid Bio hit as FDA slaps clinical hold on DMD gene therapyThe FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid Share XSolid Bio hit as FDA slaps clinical hold on DMD gene therapyhttps://pharmaphorum.com/news/solid-bio-hit-as-fda-slaps-clinical-hold-on-dmd-gene-therapy/
Roche joins others in dropping myostatin inhibitor for DMDThe prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned Share XRoche joins others in dropping myostatin inhibitor for DMDhttps://pharmaphorum.com/news/roche-joins-others-in-dropping-myostatin-inhibitor-for-dmd/
NS Pharma steals a march on Sarepta with DMD drugJapan’s Nippon Shinyaku Pharma has filed for approval of its Duchenne muscular dystrophy (DMD) in the US, increasing Share XNS Pharma steals a march on Sarepta with DMD drughttps://pharmaphorum.com/news/ns-pharma-steals-a-march-on-sarepta-with-dmd-drug/
FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stableThe FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential Share XFDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stablehttps://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/
